Mirena Extension Trial

Trial ID or NCT#

NCT02985541

Status

not recruiting iconNOT RECRUITING

Purpose

The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding \[HMB\]) and safety will be assessed.

Official Title

Multi-center, Open-label, Uncontrolled Study to Assess Contraceptive Efficacy and Safety of Mirena During Extended Use Beyond 5 Years in Women 18 to 35 Years of Age Including a Subgroup Evaluation of Treatment Effect on Heavy Menstrual Bleeding

Eligibility Criteria

Ages Eligible for Study: 18 Years to 35 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Signed and dated informed consent* Women, 18 to 35 years of age at the time of screening (visit 1) who are currently using Mirena for contraception or for contraception and heavy menstrual bleeding. The duration of use of the current Mirena has to be at least 4 years 6 months at the start of screening phase but not more than 5 years at visit 2 and the woman is willing to continue with its use and has a continuing need for contraception.* Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
  1. * Menopausal symptoms with Follicle-stimulating hormone\>30 mIU/ml* Pregnancy or suspicion of pregnancy* Uterine bleeding of unknown etiology* Untreated acute cervicitis or vaginitis or other lower genital tract infections* Increased susceptibility to pelvic infection* Acute pelvic inflammatory disease (PID) or a history of PID unless successfully treated and which, in the investigator's opinion, has not negatively affected subject's fertility* Congenital or acquired uterine anomaly if it distorts the uterine cavity* History of, diagnosed or suspected genital or other malignancy and untreated cervical dysplasia* Any active acute liver disease or liver tumor (benign or malignant)* Clinically significant endometrial polyp(s)
View All Criteria
Show Less

Investigator(s)

Paul D. Blumenthal, MD, MPH
Paul D. Blumenthal, MD, MPH
Obstetrician and Gynecologist (OB-GYN), Family planning specialist
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus

Contact us to find out if this trial is right for you.

Contact

Kathryn Batham
650-724-7826

View on ClinicalTrials.gov